
D. A. DIROCCO\*, Y. JI, E. C. SHERER, A. KLAPARS, M. REIBARKH, J. DROPINSKI, R. MATHEW, P. MALIGRES, A. M. HYDE, J. LIMANTO, A. BRUNSKILL, R. T. RUCK, L.-C. CAMPEAU, I. W. DAVIES (MERCK & CO., INC., RAHWAY, USA) A Multifunctional Catalyst that Stereoselectively Assembles Prodrugs *Science* **2017**, *356*, 426–430.

## Catalytic Stereoselective Synthesis of Pronucleotides



[% NMR yields and diastereomeric ratios (dr) of 5'-O-phosphorylated products]

**Significance:** DiRocco and co-workers report a diastereoselective synthesis of pronucleotides from the corresponding nucleosides by a dynamic kinetic resolution of chlorophosphoramidate **1**. Whereas the reaction with *N*-methylimidazole as catalyst proceeds with almost no stereoselectivity toward the newly formed stereogenic center on phosphorus, a dimeric, chiral, imidazole-based catalyst with additional hydrogen-bonding sites furnished a series of pronucleotides in good yields

and good to excellent stereoselectivities. **SYNFACTS Contributors:** Benjamin List, Lucas Schreyer Synfacts 2017, 13(08), 0867 Published online: 18.07.2017 **DOI:** 10.1055/s-0036-1590687; **Reg-No.:** B05317SF

2017 © THIEME STUTTGART • NEW YORK

**Comment:** Pronucleotides are important compounds for the treatment of viral diseases and cancer. The derivative MK-3682, for instance, is a hepatitis C viral RNA polymerase inhibitor, currently undergoing late-stage clinical trials. Because different absolute configurations of the P-based stereogenic center can significantly alter the drug's potency and toxicity, stereoselective generation thereof is of great importance. Herein, the authors report the first catalytic, stereoselective access to compounds bearing P-based stereogenic centers.

## Category

Organo- and Biocatalysis

## Key words

pronucleotides

P-based stereogenic centers

nucleosides

medicinal chemistry

